Ambrisentan
Ambrisentan, sold as Letairis, is an endothelin receptor antagonist. The US label lists treating pulmonary arterial hypertension (WHO Group 1) in adult patients, to improve exercise ability and delay clinical worsening; it also lists a second use, together with tadalafil, that this page does not describe. The label carries a boxed warning for embryo-fetal toxicity: it says the medicine is contraindicated during pregnancy because it may cause major birth defects. That risk concerns the unborn child and is recorded separately.
Also called LETAIRIS
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 358274; UNII HW6NV07QEC. MeSH has no descriptor for ambrisentan (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Endothelin Receptor Antagonist, so the record is filed under the class page. The label read is the Gilead Sciences, Inc. label for Letairis, application NDA022081 (approved 2007-06-15 as a new molecular entity in Drugs@FDA), effective 2026-06-22 in openFDA. The label's second indication, in combination with tadalafil, is not recorded. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the boxed-warning title and one sentence, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label describes ambrisentan as an antagonist of the endothelin receptor subtype ET A, with high selectivity for ET A over ET B.
Claims and evidence
Context Adults with pulmonary arterial hypertension, as described in the US label of Letairis
- Recipient
- Adult
- Population
- Adult patients with pulmonary arterial hypertension (WHO Group 1), as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adult patients with pulmonary arterial hypertension (WHO Group 1), as the label states.
- Excluded
- None stated
The US label of Letairis (ambrisentan tablets, Gilead Sciences, Inc., application NDA022081; the version dated 2026-06-22 in openFDA) describes ambrisentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group 1) in adult patients to improve exercise ability and delay clinical worsening.
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Letairis
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists use in combination with tadalafil; that indication is not recorded here. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists a use in combination with tadalafil; that use is not recorded here.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA022081.
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260622.
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K29-LET-LB-04, Q-K29-LET-LB-05).
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context The developing fetus, for a person taking ambrisentan during pregnancy, as described in a US label boxed warning
- Recipient
- Fetal
- Population
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Excluded
- None stated
The same US label of Letairis carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause major birth defects if used by pregnant patients.
Applies to Fetal The developing fetus, for a person taking ambrisentan during pregnancy, as described in a US label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA022081.
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260622.
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (Q-K29-LET-LB-06).
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first paragraph
- How it applies
- Label passage quoted in the research quote table (Q-K29-LET-LB-07).
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In pregnancy 1
The same US label of Letairis carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause major birth defects if used by pregnant patients.
Applies to Fetal The developing fetus, for a person taking ambrisentan during pregnancy, as described in a US label boxed warning
Population, setting and follow-up
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA022081.
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260622.
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (Q-K29-LET-LB-06).
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first paragraph
- How it applies
- Label passage quoted in the research quote table (Q-K29-LET-LB-07).
- Retrieved
- Source effective date
- 2026-06-22
- Source state
- Current
- Version fingerprint
cb05e7ec98fb9125e297e83359e1d7f8e8c891190cd31f15b0ff03aecd82f4d6- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists pulmonary arterial hypertension (WHO Group 1) in adult patients, to improve exercise ability and delay clinical worsening, as an indication: Pulmonary arterial hypertension
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Letairis
The US label of Letairis (ambrisentan tablets, Gilead Sciences, Inc., application NDA022081; the version dated 2026-06-22 in openFDA) describes ambrisentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group 1) in adult patients to improve exercise ability and delay clinical worsening.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists use in combination with tadalafil; that indication is not recorded here. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists a use in combination with tadalafil; that use is not recorded here.
Record details
- Record id
cardio:ambrisentan- Content hash
a0fd9281afd23fa33eeee526d43f98df57e87d98616b628409c7cdea5062ab84